Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00546364 · ClinicalTrials.gov registry record · Phase 2
Randomized Study Evaluating Ixabepilone Plus Capecitabine or Docetaxel Plus Capecitabine in Metastatic Breast Cancer
A Phase 2 study, sponsored by R-Pharm.
- Terminated
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
NCT00546364 is a Phase 2 study that was terminated before completion, run by R-Pharm. The registered enrollment target is 62 participants.
The verdict
NCT00546364, a Phase 2 study, was terminated before completion, sponsored by R-Pharm.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effect of ixabepilone plus capecitabine or docetaxel plus capecitabine on shrinking or slowing the growth of metastatic breast cancer in women. The safety of this combination therapy will also be evaluated.
Interventions
- DRUG Ixabepilone, 40 mg/m^2 + Capecitabine, 1000 mg/m^2
- DRUG Ixabepilone, 32 mg/m^2 + Capecitabine, 1000 mg/m^2
- DRUG Docetaxel, 75 mg/m^2 + Capecitabine, 1000 mg/m^2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2008-02 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00546364
The ClinicalTrials.gov registry entry for NCT00546364 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is R-Pharm, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ixabepilone, 40 mg/m^2 + Capecitabine, 1000 mg/m^2 is the first listed.
NCT00546364 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00546364 about?
NCT00546364 is a clinical study titled "Randomized Study Evaluating Ixabepilone Plus Capecitabine or Docetaxel Plus Capecitabine in Metastatic Breast Cancer". The purpose of this study is to assess the effect of ixabepilone plus capecitabine or docetaxel plus capecitabine on shrinking or slowing the growth of metastatic breast cancer in women. The safety of this combination therapy will also be evaluated.
What is the current status of trial NCT00546364?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2008-02. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00546364?
The interventions under investigation include: Ixabepilone, 40 mg/m^2 + Capecitabine, 1000 mg/m^2 (DRUG), Ixabepilone, 32 mg/m^2 + Capecitabine, 1000 mg/m^2 (DRUG), Docetaxel, 75 mg/m^2 + Capecitabine, 1000 mg/m^2 (DRUG).
Who is sponsoring clinical trial NCT00546364?
This trial is sponsored by R-Pharm, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.